1
|
Abera A, Tegally H, Tasew G, Wilkinson E, Ali A, Regasa F, Bitew M, Chabuka L, Mwanyika G, Tshiabuila D, Giandhari J, Pillay S, Poogavanan J, Moir M, Kraemer MUG, Khan K, Huber C, Tollera G, de Wit TFR, Baxter C, Lessells R, Wolday D, Beyene D, de Oliveira T. Genomic characterization of Dengue virus circulation in Ethiopia. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.07.10.24310195. [PMID: 39040196 PMCID: PMC11261913 DOI: 10.1101/2024.07.10.24310195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/24/2024]
Abstract
In Ethiopia, dengue virus (DENV) infections have been reported in several regions, however, little is known about the circulating genetic diversity. Here, we conducted clinical surveillance for DENV during the 2023 nationwide outbreak and sequenced DENV whole genomes for the first time in Ethiopia. We enrolled patients at three sentinel hospital sites. Using RT-PCR, we screened serum samples for three arboviruses followed by serotyping and sequencing for DENV-positive samples (10.4% of samples). We detected two DENV serotypes (DENV1 and DENV3). Phylogenetic analysis identified one transmission cluster of DENV1 (genotype III major lineage A), and two clusters of DENV3 (genotype III major lineage B). The first showed close evolutionary relationship to the 2023 Italian outbreak and the second cluster to Indian isolates. Co-circulation of DENV1 and DENV3 in some regions of Ethiopia highlights the potential for severe dengue. Intensified surveillance and coordinated public health response are needed to address the threat of severe dengue outbreaks.
Collapse
|
2
|
Bane S, Rosenke K, Feldmann F, Meade-White K, Diawara S, Keita M, Maiga O, Diakite M, Safronetz D, Doumbia S, Sogoba N, Feldmann H. Seroprevalence of Arboviruses in a Malaria Hyperendemic Area in Southern Mali. Am J Trop Med Hyg 2024; 111:107-112. [PMID: 38834052 PMCID: PMC11229645 DOI: 10.4269/ajtmh.23-0803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2023] [Accepted: 03/12/2024] [Indexed: 06/06/2024] Open
Abstract
Diagnostics for febrile illnesses other than malaria are not readily available in rural sub-Saharan Africa. This study assessed exposure to three mosquito-borne arboviruses-dengue virus (DENV), Zika virus (ZIKV), and chikungunya virus (CHIKV)-in southern Mali. Seroprevalence for DENV, CHIKV, and ZIKV was analyzed by detection of IgG antibodies and determined to be 77.2%, 31.2%, and 25.8%, respectively. Among study participants, 11.3% were IgG-positive for all three arboviruses. DENV had the highest seroprevalence rate at all sites; the highest seroprevalence of CHIKV and ZIKV was observed in Bamba. The seroprevalence for all three arboviruses increased with age, and the highest seroprevalence was observed among adults older than 50 years. The prevalence of Plasmodium spp. in the cohort was analyzed by microscopy and determined to be 44.5% (N = 600) with Plasmodium falciparum representing 95.1% of all infections. This study demonstrates the co-circulation of arboviruses in a region hyperendemic for malaria and highlights the needs for arbovirus diagnostics in rural sub-Saharan Africa.
Collapse
Affiliation(s)
- Sidy Bane
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Kyle Rosenke
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana
| | - Friederike Feldmann
- Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana
| | - Kimberly Meade-White
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana
| | - Sory Diawara
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Moussa Keita
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Ousmane Maiga
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Mahamadou Diakite
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - David Safronetz
- Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
| | - Seydou Doumbia
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Nafomon Sogoba
- University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Heinz Feldmann
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana
| |
Collapse
|
3
|
Mensah EA, Gyasi SO, Nsubuga F, Alali WQ. A proposed One Health approach to control yellow fever outbreaks in Uganda. ONE HEALTH OUTLOOK 2024; 6:9. [PMID: 38783349 PMCID: PMC11119388 DOI: 10.1186/s42522-024-00103-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Accepted: 04/26/2024] [Indexed: 05/25/2024]
Abstract
Yellow Fever (YF) is an acute viral hemorrhagic disease. Uganda is located within the Africa YF belt. Between 2019 and 2022, the Ugandan Health Authorities reported at least one outbreak of YF annually with an estimated 892 suspected cases, on average per year. The persistent recurrence of this disease raises significant concerns about the efficacy of current response strategies and prevention approaches. YF has been recognized as a One Health issue due to its interrelatedness with the animal and environmental domains. Monkeys have been recognized as the virus primary reservoir. The YF virus is transmitted through bites of infected Aedes or Haemagogus species mosquitoes between monkeys and humans. Human activities, monkey health, and environmental health issues (e.g., climate change and land use) impact YF incidence in Uganda. Additionally, disease control programs for other tropical diseases, such as mosquitoes control programs for malaria, impact YF incidence.This review adopts the One Health approach to highlight the limitations in the existing segmented YF control and prevention strategies in Uganda, including the limited health sector surveillance, the geographically localized outbreak response efforts, the lack of a comprehensive vaccination program, the limited collaboration and communication among relevant national and international agencies, and the inadequate vector control practices. Through a One Health approach, we propose establishing a YF elimination taskforce. This taskforce would oversee coordination of YF elimination initiatives, including implementing a comprehensive surveillance system, conducting mass YF vaccination campaigns, integrating mosquito management strategies, and enhancing risk communication. It is anticipated that adopting the One Health approach will reduce the risk of YF incidence and outbreaks.
Collapse
Affiliation(s)
- Emmanuel Angmorteh Mensah
- Department of Biostatistics & Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN, USA
| | - Samuel Ofori Gyasi
- Department of Immunization, Vaccines and Biologicals, World Health Organization Country Office, Kampala, Uganda
| | - Fred Nsubuga
- Division of Immunization and Vaccines, Ministry of Health, Kampala, Uganda
| | - Walid Q Alali
- Department of Biostatistics & Epidemiology, College of Public Health, East Tennessee State University, Johnson City, TN, USA.
| |
Collapse
|
4
|
Kang H, Auzenbergs M, Clapham H, Maure C, Kim JH, Salje H, Taylor CG, Lim A, Clark A, Edmunds WJ, Sahastrabuddhe S, Brady OJ, Abbas K. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study. THE LANCET. INFECTIOUS DISEASES 2024; 24:488-503. [PMID: 38342105 DOI: 10.1016/s1473-3099(23)00810-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/09/2023] [Accepted: 12/14/2023] [Indexed: 02/13/2024]
Abstract
BACKGROUND Chikungunya is an arboviral disease transmitted by Aedes aegypti and Aedes albopictus mosquitoes with a growing global burden linked to climate change and globalisation. We aimed to estimate chikungunya seroprevalence, force of infection (FOI), and prevalence of related chronic disability and hospital admissions in endemic and epidemic settings. METHODS In this systematic review, meta-analysis, and modelling study, we searched PubMed, Ovid, and Web of Science for articles published from database inception until Sept 26, 2022, for prospective and retrospective cross-sectional studies that addressed serological chikungunya virus infection in any geographical region, age group, and population subgroup and for longitudinal prospective and retrospective cohort studies with data on chronic chikungunya or hospital admissions in people with chikungunya. We did a systematic review of studies on chikungunya seroprevalence and fitted catalytic models to each survey to estimate location-specific FOI (ie, the rate at which susceptible individuals acquire chikungunya infection). We performed a meta-analysis to estimate the proportion of symptomatic patients with laboratory-confirmed chikungunya who had chronic chikungunya or were admitted to hospital following infection. We used a random-effects model to assess the relationship between chronic sequelae and follow-up length using linear regression. The systematic review protocol is registered online on PROSPERO, CRD42022363102. FINDINGS We identified 60 studies with data on seroprevalence and chronic chikungunya symptoms done across 76 locations in 38 countries, and classified 17 (22%) of 76 locations as endemic settings and 59 (78%) as epidemic settings. The global long-term median annual FOI was 0·007 (95% uncertainty interval [UI] 0·003-0·010) and varied from 0·0001 (0·00004-0·0002) to 0·113 (0·07-0·20). The highest estimated median seroprevalence at age 10 years was in south Asia (8·0% [95% UI 6·5-9·6]), followed by Latin America and the Caribbean (7·8% [4·9-14·6]), whereas median seroprevalence was lowest in the Middle East (1·0% [0·5-1·9]). We estimated that 51% (95% CI 45-58) of people with laboratory-confirmed symptomatic chikungunya had chronic disability after infection and 4% (3-5) were admitted to hospital following infection. INTERPRETATION We inferred subnational heterogeneity in long-term average annual FOI and transmission dynamics and identified both endemic and epidemic settings across different countries. Brazil, Ethiopia, Malaysia, and India included both endemic and epidemic settings. Long-term average annual FOI was higher in epidemic settings than endemic settings. However, long-term cumulative incidence of chikungunya can be similar between large outbreaks in epidemic settings with a high FOI and endemic settings with a relatively low FOI. FUNDING International Vaccine Institute.
Collapse
Affiliation(s)
- Hyolim Kang
- London School of Hygiene and Tropical Medicine, London, UK; Seoul National University College of Medicine School, Seoul, South Korea.
| | | | - Hannah Clapham
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore
| | - Clara Maure
- International Vaccine Institute, Seoul, South Korea
| | | | - Henrik Salje
- Department of Genetics, Cambridge University, Cambridge, UK
| | | | - Ahyoung Lim
- London School of Hygiene and Tropical Medicine, London, UK
| | - Andrew Clark
- London School of Hygiene and Tropical Medicine, London, UK
| | - W John Edmunds
- London School of Hygiene and Tropical Medicine, London, UK; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
| | - Sushant Sahastrabuddhe
- International Vaccine Institute, Seoul, South Korea; Centre International de Recherche en Infectiologie, Université Jean Monnet, Université Claude Bernard Lyon, INSERM, Saint-Etienne, France
| | - Oliver J Brady
- London School of Hygiene and Tropical Medicine, London, UK
| | - Kaja Abbas
- London School of Hygiene and Tropical Medicine, London, UK; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
| |
Collapse
|
5
|
Saba Villarroel PM, Hamel R, Gumpangseth N, Yainoy S, Koomhin P, Missé D, Wichit S. Global seroprevalence of Zika virus in asymptomatic individuals: A systematic review. PLoS Negl Trop Dis 2024; 18:e0011842. [PMID: 38630843 PMCID: PMC11057727 DOI: 10.1371/journal.pntd.0011842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 04/29/2024] [Accepted: 04/01/2024] [Indexed: 04/19/2024] Open
Abstract
BACKGROUND Zika virus (ZIKV) has spread to five of the six World Health Organization (WHO) regions. Given the substantial number of asymptomatic infections and clinical presentations resembling those of other arboviruses, estimating the true burden of ZIKV infections is both challenging and essential. Therefore, we conducted a systematic review and meta-analysis of seroprevalence studies of ZIKV IgG in asymptomatic population to estimate its global impact and distribution. METHODOLOGY/PRINCIPAL FINDINGS We conducted extensive searches and compiled a collection of articles published from Jan/01/2000, to Jul/31/2023, from Embase, Pubmed, SciELO, and Scopus databases. The random effects model was used to pool prevalences, reported with their 95% confidence interval (CI), a tool to assess the risk of study bias in prevalence studies, and the I2 method for heterogeneity (PROSPERO registration No. CRD42023442227). Eighty-four studies from 49 countries/territories, with a diversity of study designs and serological tests were included. The global seroprevalence of ZIKV was 21.0% (95%CI 16.1%-26.4%). Evidence of IgG antibodies was identified in all WHO regions, except for Europe. Seroprevalence correlated with the epidemics in the Americas (39.9%, 95%CI:30.0-49.9), and in some Western Pacific countries (15.6%, 95%CI:8.2-24.9), as well as with recent and past circulation in Southeast Asia (22.8%, 95%CI:16.5-29.7), particularly in Thailand. Additionally, sustained low circulation was observed in Africa (8.4%, 95%CI:4.8-12.9), except for Gabon (43.7%), and Burkina Faso (22.8%). Although no autochthonous transmission was identified in the Eastern Mediterranean, a seroprevalence of 16.0% was recorded. CONCLUSIONS/SIGNIFICANCE The study highlights the high heterogeneity and gaps in the distribution of seroprevalence. The implementation of standardized protocols and the development of tests with high specificity are essential for ensuring a valid comparison between studies. Equally crucial are vector surveillance and control methods to reduce the risk of emerging and re-emerging ZIKV outbreaks, whether caused by Ae. aegypti or Ae. albopictus or by the Asian or African ZIKV.
Collapse
Affiliation(s)
- Paola Mariela Saba Villarroel
- Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
- Viral Vector Joint unit and Joint Laboratory, Mahidol University, Nakhon Pathom, Thailand
| | - Rodolphe Hamel
- Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
- Viral Vector Joint unit and Joint Laboratory, Mahidol University, Nakhon Pathom, Thailand
- MIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France
| | - Nuttamonpat Gumpangseth
- Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
- Viral Vector Joint unit and Joint Laboratory, Mahidol University, Nakhon Pathom, Thailand
| | - Sakda Yainoy
- Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
| | - Phanit Koomhin
- Center of Excellence in Innovation on Essential Oil, Walailak University, Nakhonsithammarat, Thailand
| | - Dorothée Missé
- MIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France
| | - Sineewanlaya Wichit
- Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand
- Viral Vector Joint unit and Joint Laboratory, Mahidol University, Nakhon Pathom, Thailand
| |
Collapse
|
6
|
Abdoullah B, Durand GA, Basco LK, El Bara A, Bollahi MA, Bosio L, Geulen M, Briolant S, Boukhary AOMS. Seroprevalence of Alphaviruses ( Togaviridae) among Urban Population in Nouakchott, Mauritania, West Africa. Viruses 2023; 15:1588. [PMID: 37515274 PMCID: PMC10385508 DOI: 10.3390/v15071588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 07/13/2023] [Accepted: 07/17/2023] [Indexed: 07/30/2023] Open
Abstract
The presence of alphaviruses, such as chikungunya virus (CHIKV), has never been reported in Mauritania. We assessed the seroprevalence of CHIKV among Nouakchott residents. A cross-sectional study involving 1300 non-febrile patients consulting at the Nouakchott hospital center was conducted between January and June 2021. The presence of anti-CHIKV IgG and neutralizing antibodies against CHIKV, O'nyong-nyong virus (ONNV), and Semliki Forest virus (SFV) was determined by an enzyme-linked immunosorbent assay (ELISA) and a serum neutralization test, respectively, and the associated risk factors were investigated. Of the 1300 study participants, serological evidence of previous exposure to CHIKV was observed in 37 individuals (2.8%). Sex, age, reported use of repellants, and bed net ownership and usage were not associated with CHIKV seropositivity. Our results showed the co-circulation of two other alphaviruses, ONNV and SFV, in Nouakchott in 30 (2.3%) individuals. This is the first study that documents the co-circulation of CHIKV, ONNV, and SFV in Mauritania, albeit at low prevalence. Surveillance and routine testing for alphaviruses and other arboviruses in symptomatic patients should be implemented in health facilities to assess the health burden associated with these viruses. Efforts should also be made to strengthen the vector control measures.
Collapse
Affiliation(s)
- Bedia Abdoullah
- Unité de Recherche Génomes et Milieux (GEMI), Université de Nouakchott, Nouveau Campus Universitaire, Nouakchott BP 5026, Mauritania
| | - Guillaume André Durand
- National Reference Center for Arboviruses, National Institute of Health and Medical Research (Inserm) and French Armed Forces Biomedical Research Institute (IRBA), 13005 Marseille, France
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), 13005 Marseille, France
| | - Leonardo K Basco
- Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, 13005 Marseille, France
- IHU-Méditerranée Infection, 13005 Marseille, France
| | - Ahmed El Bara
- Institut National de Recherche en Santé Publique, Nouakchott BP 695, Mauritania
| | | | - Laurent Bosio
- National Reference Center for Arboviruses, National Institute of Health and Medical Research (Inserm) and French Armed Forces Biomedical Research Institute (IRBA), 13005 Marseille, France
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), 13005 Marseille, France
| | - Manon Geulen
- National Reference Center for Arboviruses, National Institute of Health and Medical Research (Inserm) and French Armed Forces Biomedical Research Institute (IRBA), 13005 Marseille, France
- Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), 13005 Marseille, France
| | - Sébastien Briolant
- Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, 13005 Marseille, France
- IHU-Méditerranée Infection, 13005 Marseille, France
- Unité de Parasitologie Entomologie, Département de Microbiologie et Maladies Infectieuses, Institut de Recherche Biomédicale des Armées (IRBA), 13005 Marseille, France
| | - Ali Ould Mohamed Salem Boukhary
- Unité de Recherche Génomes et Milieux (GEMI), Université de Nouakchott, Nouveau Campus Universitaire, Nouakchott BP 5026, Mauritania
| |
Collapse
|
7
|
Mac PA, Kroeger A, Daehne T, Anyaike C, Velayudhan R, Panning M. Zika, Flavivirus and Malaria Antibody Cocirculation in Nigeria. Trop Med Infect Dis 2023; 8:tropicalmed8030171. [PMID: 36977172 PMCID: PMC10059970 DOI: 10.3390/tropicalmed8030171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 03/08/2023] [Accepted: 03/10/2023] [Indexed: 03/15/2023] Open
Abstract
Introduction. Arboviruses and malaria pose a growing threat to public health, affecting not only the general population but also immunocompromised individuals and pregnant women. Individuals in vulnerable groups are at a higher risk of severe complications from the co-circulation and transmission of ZIKV, malaria, and FLAVI fever. In sub-Saharan countries, such as Nigeria, these mosquito-borne infections have clinical presentations that overlap with other diseases (dengue, West Nile virus, and Japanese encephalitis, chikungunya, and O’nyong o’nyong virus), making them a diagnostic challenge for clinicians in regions where they co-circulate. Vertical transmission can have a devastating impact on maternal health and fetal outcomes, including an increased risk of fetal loss and premature birth. Despite the global recognition of the burden of malaria and arboviruses, particularly ZIKV and other flaviviruses, there is limited data on their prevalence in Nigeria. In urban settings, where these diseases are endemic and share common biological, ecological, and economic factors, they may impact treatment outcomes and lead to epidemiological synergy. Hence, it is imperative to conduct sero-epidemiological and clinical studies to better understand the disease burden and hidden endemicity, thereby enabling improved prevention and clinical management. Method. Serum samples collected from outpatients between December 2020 and November 2021 in three regions of Nigeria were tested for the presence of IgG antibody seropositivity against ZIKV and FLAVI using immunoblot serological assay. Results. The overall cohort co-circulation antibody seropositivity of ZIKV, FLAVI and malaria was 24.0% (209/871). A total of 19.2% (167/871) of the study participants had ZIKV-seropositive antibodies and 6.2% (54/871) were FLAVI-seropositive, while 40.0% (348/871) of the subjects had malaria parasite antigens. Regional analysis revealed that participants from the southern region had the highest antibody seropositivity against ZIKV (21.7% (33/152)) and FLAVI (8.6% (13/152)), whereas those from the central region had a higher malaria parasite antigen (68.5% (287/419)). Conclusions. This study represents the largest comparative cross-sectional descriptive sero-epidemiological investigation of ZIKV-FLAVI and malaria cocirculation in Nigeria. The findings of this study revealed increased antibody seropositivity, hidden endemicity, and the burden of ZIKV, FLAVI, and malaria co-circulating in Nigeria.
Collapse
Affiliation(s)
- Peter Asaga Mac
- Institute of Virologie Hermann Herder Strabe, Universitatsklinikum Freiburg, 79104 Freiburg, Germany
- Correspondence:
| | - Axel Kroeger
- Centre for Medicine and Society, University of Freiburg, 79085 Freiburg, Germany
| | - Theo Daehne
- Institute of Virologie Hermann Herder Strabe, Universitatsklinikum Freiburg, 79104 Freiburg, Germany
| | | | | | - Marcus Panning
- Institute of Virologie Hermann Herder Strabe, Universitatsklinikum Freiburg, 79104 Freiburg, Germany
| |
Collapse
|
8
|
Rosinski JR, Raasch LE, Barros Tiburcio P, Breitbach ME, Shepherd PM, Yamamoto K, Razo E, Krabbe NP, Bliss MI, Richardson AD, Einwalter MA, Weiler AM, Sneed EL, Fuchs KB, Zeng X, Noguchi KK, Morgan TK, Alberts AJ, Antony KM, Kabakov S, Ausderau KK, Bohm EK, Pritchard JC, Spanton RV, Ver Hoove JN, Kim CBY, Nork TM, Katz AW, Rasmussen CA, Hartman A, Mejia A, Basu P, Simmons HA, Eickhoff JC, Friedrich TC, Aliota MT, Mohr EL, Dudley DM, O’Connor DH, Newman CM. Frequent first-trimester pregnancy loss in rhesus macaques infected with African-lineage Zika virus. PLoS Pathog 2023; 19:e1011282. [PMID: 36976812 PMCID: PMC10081769 DOI: 10.1371/journal.ppat.1011282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 04/07/2023] [Accepted: 03/08/2023] [Indexed: 03/29/2023] Open
Abstract
In the 2016 Zika virus (ZIKV) pandemic, a previously unrecognized risk of birth defects surfaced in babies whose mothers were infected with Asian-lineage ZIKV during pregnancy. Less is known about the impacts of gestational African-lineage ZIKV infections. Given high human immunodeficiency virus (HIV) burdens in regions where African-lineage ZIKV circulates, we evaluated whether pregnant rhesus macaques infected with simian immunodeficiency virus (SIV) have a higher risk of African-lineage ZIKV-associated birth defects. Remarkably, in both SIV+ and SIV- animals, ZIKV infection early in the first trimester caused a high incidence (78%) of spontaneous pregnancy loss within 20 days. These findings suggest a significant risk for early pregnancy loss associated with African-lineage ZIKV infection and provide the first consistent ZIKV-associated phenotype in macaques for testing medical countermeasures.
Collapse
Affiliation(s)
- Jenna R. Rosinski
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Lauren E. Raasch
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Patrick Barros Tiburcio
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Meghan E. Breitbach
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Phoenix M. Shepherd
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Keisuke Yamamoto
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Elaina Razo
- Department of Pediatrics, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Nicholas P. Krabbe
- Department of Pediatrics, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Mason I. Bliss
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Alexander D. Richardson
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Morgan A. Einwalter
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Andrea M. Weiler
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Emily L. Sneed
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Kerri B. Fuchs
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Xiankun Zeng
- United States Army Medical Research Institute of Infectious Diseases; Fort Detrick, Maryland, Unites States of America
| | - Kevin K. Noguchi
- Department of Psychiatry, Washington University School of Medicine; St. Louis, Washington, Unites States of America
| | - Terry K. Morgan
- Department of Pathology, Oregon Health and Science University; Portland, Oregon, Unites States of America
- Department of Obstetrics and Gynecology, Oregon Health and Science University; Portland, Oregon, Unites States of America
| | - Alexandra J. Alberts
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Kathleen M. Antony
- Department of Obstetrics and Gynecology, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Sabrina Kabakov
- Department of Kinesiology, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Karla K. Ausderau
- Department of Kinesiology, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
- Waisman Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Ellie K. Bohm
- Department of Veterinary and Biomedical Science, University of Minnesota; St. Paul, Minnesota, Unites States of America
| | - Julia C. Pritchard
- Department of Veterinary and Biomedical Science, University of Minnesota; St. Paul, Minnesota, Unites States of America
| | - Rachel V. Spanton
- Department of Kinesiology, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - James N. Ver Hoove
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Charlene B. Y. Kim
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - T. Michael Nork
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Alex W. Katz
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Carol A. Rasmussen
- Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Amy Hartman
- Department of Communication Sciences and Disorders, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Andres Mejia
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Puja Basu
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Heather A. Simmons
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Jens C. Eickhoff
- Department of Biostatistics & Medical Informatics, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Thomas C. Friedrich
- Department of Pathobiological Sciences, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Matthew T. Aliota
- Department of Veterinary and Biomedical Science, University of Minnesota; St. Paul, Minnesota, Unites States of America
| | - Emma L. Mohr
- Department of Pediatrics, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Dawn M. Dudley
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - David H. O’Connor
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
- Wisconsin National Primate Research Center, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| | - Christina M. Newman
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison; Madison, Wisconsin, Unites States of America
| |
Collapse
|
9
|
Setlur AS, K C, Pandey S, Sarkar M, Niranjan V. Comprehensive Molecular Interaction Studies to Construe the Repellent/Kill Activity of Geraniol During Binding Event Against Aedes aegypti Proteins. Mol Biotechnol 2022; 65:726-740. [PMID: 36169809 DOI: 10.1007/s12033-022-00560-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2022] [Accepted: 09/06/2022] [Indexed: 11/27/2022]
Abstract
Aedes aegypti is an etiological agent for dengue, chikungunya, zika, and yellow fever viruses. With the advent of the use of natural alternatives as repellents, their precise mode of action during the event of binding is still unclear. Geraniol is one such bioactive natural that has been previously shown to have some insecticide properties. Thus, the present study aimed to understand the mechanism of the binding event of geraniol with the whole proteome of A. aegypti. Twenty protein target categories were shortlisted for the mosquito, wherein the proteins were downloaded with respect to the reference proteome. Conserved domain analysis was performed for the same using the CDD search tool to find the proteins that have common domains. 309 proteins were modeled using RaptorX standalone tool, and validated using Ramachandran plots from SAVES v6.0 from ProCheck. These modeled and validated proteins were then docked against geraniol, using POAP software, for understanding the binding energies. The top 3 best-docked complexes were then analyzed for their stabilities and event of binding via 100 ns simulation studies using DESMOND's Maestro environment. The docking results showed that the geraniol-voltage-gated sodium channel had the best energy of - 7.1 kcal/mol, followed by geraniol-glutathione-S-transferase (- 6.8 kcal/mol) and geraniol-alpha esterase (- 6.8 kcal/mol). The simulations for these 3 complexes revealed that several residues of the proteins interacted well with geraniol at a molecular level, and all three docked complexes were found to be stable when simulated (RMSD: 16-18 Å, 3.6-4.8 Å, 4.8-5.6 Å, respectively). Thus, the present study provides insights into the mechanism of the binding event of geraniol with the major A. aegypti targets, thereby, assisting the use of geraniol as a natural repellent.
Collapse
Affiliation(s)
- Anagha S Setlur
- Department of Biotechnology, RV College of Engineering, Bangalore, 560059, India
| | - Chandrashekar K
- Department of Biotechnology, RV College of Engineering, Bangalore, 560059, India
| | - Shruti Pandey
- Research and Development, Reckitt Benckiser India Pvt. Ltd., Gurgaon, Haryana, 122001, India
| | - Manas Sarkar
- Research and Development, Reckitt Benckiser India Pvt. Ltd., Gurgaon, Haryana, 122001, India
| | - Vidya Niranjan
- Department of Biotechnology, RV College of Engineering, Bangalore, 560059, India.
| |
Collapse
|
10
|
Oyono MG, Kenmoe S, Abanda NN, Takuissu GR, Ebogo-Belobo JT, Kenfack-Momo R, Kengne-Nde C, Mbaga DS, Tchatchouang S, Kenfack-Zanguim J, Lontuo Fogang R, Zeuko’o Menkem E, Ndzie Ondigui JL, Kame-Ngasse GI, Magoudjou-Pekam JN, Bowo-Ngandji A, Nkie Esemu S, Ndip L. Epidemiology of yellow fever virus in humans, arthropods, and non-human primates in sub-Saharan Africa: A systematic review and meta-analysis. PLoS Negl Trop Dis 2022; 16:e0010610. [PMID: 35867659 PMCID: PMC9307179 DOI: 10.1371/journal.pntd.0010610] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Accepted: 06/27/2022] [Indexed: 12/13/2022] Open
Abstract
Yellow fever (YF) has re-emerged in the last two decades causing several outbreaks in endemic countries and spreading to new receptive regions. This changing epidemiology of YF creates new challenges for global public health efforts. Yellow fever is caused by the yellow fever virus (YFV) that circulates between humans, the mosquito vector, and non-human primates (NHP). In this systematic review and meta-analysis, we review and analyse data on the case fatality rate (CFR) and prevalence of YFV in humans, and on the prevalence of YFV in arthropods, and NHP in sub-Saharan Africa (SSA). We performed a comprehensive literature search in PubMed, Web of Science, African Journal Online, and African Index Medicus databases. We included studies reporting data on the CFR and/or prevalence of YFV. Extracted data was verified and analysed using the random effect meta-analysis. We conducted subgroup, sensitivity analysis, and publication bias analyses using the random effect meta-analysis while I2 statistic was employed to determine heterogeneity. This review was registered with PROSPERO under the identification CRD42021242444. The final meta-analysis included 55 studies. The overall case fatality rate due to YFV was 31.1% (18.3–45.4) in humans and pooled prevalence of YFV infection was 9.4% (6.9–12.2) in humans. Only five studies in West and East Africa detected the YFV in mosquito species of the genus Aedes and in Anopheles funestus. In NHP, YFV antibodies were found only in members of the Cercopithecidae family. Our analysis provides evidence on the ongoing circulation of the YFV in humans, Aedes mosquitoes and NHP in SSA. These observations highlight the ongoing transmission of the YFV and its potential to cause large outbreaks in SSA. As such, strategies such as those proposed by the WHO’s Eliminate Yellow Fever Epidemics (EYE) initiative are urgently needed to control and prevent yellow fever outbreaks in SSA.
Collapse
Affiliation(s)
- Martin Gael Oyono
- Centre for Research on Health and Priority Pathologies, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
- Laboratory of Parasitology and Ecology, Department of Animal Biology and Physiology, University of Yaounde I, Yaounde, Cameroon
| | - Sebastien Kenmoe
- Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
- * E-mail:
| | - Ngu Njei Abanda
- Virology Department, Centre Pasteur of Cameroon, Yaounde, Cameroon
| | - Guy Roussel Takuissu
- Centre for Food, Food Security and Nutrition Research, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
| | - Jean Thierry Ebogo-Belobo
- Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
| | - Raoul Kenfack-Momo
- Department of Biochemistry, The University of Yaounde I, Yaounde, Cameroon
| | - Cyprien Kengne-Nde
- Epidemiological Surveillance, Evaluation and Research Unit, National AIDS Control Committee, Douala, Cameroon
| | | | | | | | | | | | | | - Ginette Irma Kame-Ngasse
- Medical Research Centre, Institute of Medical Research and Medicinal Plants Studies, Yaounde, Cameroon
| | | | - Arnol Bowo-Ngandji
- Department of Microbiology, The University of Yaounde I, Yaounde, Cameroon
| | | | - Lucy Ndip
- Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
| |
Collapse
|
11
|
Madzokere ET, Qian W, Webster JA, Walker DMH, Lim EXY, Harley D, Herrero LJ. Human Seroprevalence for Dengue, Ross River, and Barmah Forest viruses in Australia and the Pacific: A systematic review spanning seven decades. PLoS Negl Trop Dis 2022; 16:e0010314. [PMID: 35486651 PMCID: PMC9094520 DOI: 10.1371/journal.pntd.0010314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2021] [Revised: 05/11/2022] [Accepted: 03/08/2022] [Indexed: 11/18/2022] Open
Abstract
Background
Dengue (DENV), Ross River (RRV) and Barmah Forest viruses (BFV) are the most common human arboviral infections in Australia and the Pacific Island Countries and Territories (PICTs) and are associated with debilitating symptoms. All are nationally notifiable in Australia, but routine surveillance is limited to a few locations in the PICTs. Understanding the level of human exposure to these viruses can inform disease management and mitigation strategies. To assess the historic and current seroprevalence of DENV, RRV and BFV in Australia and the PICTs we conducted a systematic literature review of all published quantitative serosurveys.
Methodology and principal findings
The Preferred Reporting of Items for Systematic Reviews and Meta-Analyses procedures were adopted to produce a protocol to systematically search for published studies reporting the seroprevalence of DENV, RRV and BFV in Australia and the PICTs. Data for author, research year, location, study population, serosurvey methods and positive tests were extracted. A total of 41 papers, reporting 78 serosurveys of DENV, RRV and BFV including 62,327 samples met the inclusion criteria for this review. Seroprevalence varied depending on the assay used, strategy of sample collection and location of the study population. Significant differences were observed in reported seropositivity depending on the sample collection strategy with clinically targeted sampling reporting the highest seroprevalence across all three viruses. Non-stratified seroprevalence showed wide ranges in reported positivity with DENV 0.0% – 95.6%, RRV 0.0% – 100.0%, and BFV 0.3% – 12.5%. We discuss some of the causes of variation including serological methods used, selection bias in sample collection including clinical or environmental associations, and location of study site. We consider the extent to which serosurveys reflect the epidemiology of the viruses and provide broad recommendations regarding the conduct and reporting of arbovirus serosurveys.
Conclusions and significance
Human serosurveys provide important information on the extent of human exposure to arboviruses across: (1) time, (2) place, and (3) person (e.g., age, gender, clinical presentation etc). Interpreting results obtained at these scales has the potential to inform us about transmission cycles, improve diagnostic surveillance, and mitigate future outbreaks. Future research should streamline methods and reduce bias to allow a better understanding of the burden of these diseases and the factors associated with seroprevalence. Greater consideration should be given to the interpretation of seroprevalence in studies, and increased rigour applied in linking seroprevalence to transmission dynamics.
Collapse
Affiliation(s)
- Eugene T. Madzokere
- Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Australia
| | - Wei Qian
- Centre for Clinical Research, University of Queensland, Brisbane, Australia
| | - Julie A. Webster
- Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Australia
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Daniel M. H. Walker
- Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Australia
| | - Elisa X. Y. Lim
- Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Australia
| | - David Harley
- Centre for Clinical Research, University of Queensland, Brisbane, Australia
| | - Lara J. Herrero
- Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Australia
- * E-mail:
| |
Collapse
|
12
|
Model-based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a serological cross-reactivity context. Nat Commun 2021; 12:6735. [PMID: 34795213 PMCID: PMC8602252 DOI: 10.1038/s41467-021-26707-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 09/08/2021] [Indexed: 11/08/2022] Open
Abstract
Serological surveys are essential to quantify immunity in a population but serological cross-reactivity often impairs estimates of the seroprevalence. Here, we show that modeling helps addressing this key challenge by considering the important cross-reactivity between Chikungunya (CHIKV) and O'nyong-nyong virus (ONNV) as a case study. We develop a statistical model to assess the epidemiology of these viruses in Mali. We additionally calibrate the model with paired virus neutralization titers in the French West Indies, a region with known CHIKV circulation but no ONNV. In Mali, the model estimate of ONNV and CHIKV prevalence is 30% and 13%, respectively, versus 27% and 2% in non-adjusted estimates. While a CHIKV infection induces an ONNV response in 80% of cases, an ONNV infection leads to a cross-reactive CHIKV response in only 22% of cases. Our study shows the importance of conducting serological assays on multiple cross-reactive pathogens to estimate levels of virus circulation.
Collapse
|